- Home
- WEC vs TEVA Comparison
WEC vs TEVA Comparison
Compare WEC & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEC | TEVA |
|---|---|---|
| Founded | 1896 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3B | 37.1B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | WEC | TEVA |
|---|---|---|
| Price | $113.37 | $32.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $120.08 | $38.63 |
| AVG Volume (30 Days) | 1.9M | ★ 5.1M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.81 | N/A |
| Revenue | ★ $9,800,100,000.00 | N/A |
| Revenue This Year | $5.63 | N/A |
| Revenue Next Year | $6.58 | $2.97 |
| P/E Ratio | ★ $23.75 | $28.19 |
| Revenue Growth | ★ 13.96 | N/A |
| 52 Week Low | $102.95 | $14.99 |
| 52 Week High | $119.91 | $37.35 |
Technical Indicators
Market Signals| Indicator | WEC | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 42.35 |
| Support Level | $112.14 | $30.59 |
| Resistance Level | $113.33 | $32.40 |
| Average True Range (ATR) | 2.06 | 0.89 |
| MACD | -0.48 | -0.19 |
| Stochastic Oscillator | 12.95 | 18.14 |
Price Performance
Historical ComparisonAbout WEC WEC Energy Group Inc.
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 32% gas distribution, 10% electric transmission, 7% unregulated renewable energy, and 2% LNG distribution and generation.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.